European Hematology Association Congress | Conference

Front-MIND Aims to Examine Tafasitamab Triplet in DLBCL

June 14th 2021

Tafasitamab-cxix plus lenalidomide and R-CHOP may have synergistic potential and could represent a potential future treatment option for patients with newly diagnosed diffuse large B-cell lymphoma.

Deep Responses Yielded With Daratumumab Plus CyBorD Followed by Daratumumab Maintenance in Multiple Myeloma

June 14th 2021

For patients with newly diagnosed or relapsed multiple myeloma, regardless of transplant status, daratumumab plus cyclophosphamide, bortezomib, and dexamethasone induction followed by daratumumab maintenance therapy achieved durable and deep responses.

Cilta-Cel Induces Deep, Durable Responses in Relapsed/Refractory Multiple Myeloma

June 13th 2021

Ciltacabtagene autoleucel continued to yield early, deep, and durable responses after longer follow-up in patients with relapsed/refractory multiple myeloma.

Early Intervention For Neurotoxicity Can Improve Outcomes With Cilta-Cel in Relapsed/Refractory Multiple Myeloma

June 13th 2021

Neurologic adverse effect associated with CAR T-cell therapies like ciltacabtagene autoleucel can be managed without long-term lasting effects, as long as they are caught and treated promptly in patients with relapsed/refractory multiple myeloma.

Brexucabtagene Autoleucel Safe, Efficacious as Therapy for Pediatric B-Cell ALL in ZUMA-4

June 13th 2021

Real-World Treatment Reveals Discrepancy Between Actual Care and Clinical Trial Recommendations in MCL

June 12th 2021

A study of treatment patterns in adult patients with mantle cell lymphoma revealed a discrepancy between actual patterns of care and recommendations based on clinical trials.

Axi-Cel Induces Superior Responses, Survival in Relapsed/Refractory Follicular Lymphoma

June 12th 2021

Compared to currently available therapies, treatment with axicabtagene ciloleucel induced substantial objective response rate, progression-free survival, time to next treatment and overall survival improvements in patients with relapsed/refractory follicular lymphoma.

Naratuximab Emtansine/Rituximab Combo Elicits Clinical Activity in Relapsed/Refractory DLBCL

June 12th 2021

The combination of naratuximab emtansine and rituximab yielded deep responses, and a duration of response that was not reached in patients with relapsed or refractory diffuse large B-cell lymphoma.

Daratumumab Plus Standard of Care Continues to Improve Survival in Newly Diagnosed Multiple Myeloma

June 12th 2021

The addition of daratumumab to lenalidomide and dexamethasone continued to reduced the risk of death by 32% compared with Rd alone in patients with newly diagnosed multiple myeloma who are transplant ineligible after almost 5 years of follow-up.

Frontline Ibrutinib/Venetoclax Yields Superior Outcomes Vs Chlorambucil/Obinutuzumab in CLL

June 12th 2021

Fixed-duration ibrutinib and venetoclax as a first-line treatment yielded superior progression-free survival compared with chlorambucil plus obinutuzumab in patients with chronic lymphocytic leukemia.

Rusfertide Eliminates Need for Phlebotomy, Reverses Iron Deficiency in Polycythemia Vera

June 12th 2021

Rusfertide has been shown to be an effective option for patients with polycythemia vera in that it reverses iron deficiency, improves disease-related symptoms, and eliminates the need for therapeutic phlebotomy.

Daratumumab Maintenance Prolongs Responses Following ASCT and Standard Consolidation/Induction in Myeloma

June 12th 2021

Daratumumab maintenance therapy yielded an increase in response following autologous stem cell transplant plus induction and consolidation therapy with bortezomib, thalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma.

Dr. Ghia on the Efficacy of Ibrutinib/Venetoclax in CLL

June 12th 2021

Paolo Ghia, MD, PhD, discusses results seen with the combination of ibrutinib and venetoclax as a first-line treatment for patients with chronic lymphocytic leukemia.

Real-World Data Highlight Utility of Axi-Cel/Tisa-Cel in DLBCL

June 12th 2021

In the first few years of their availability in the United States, axicabtagene ciloleucel and tisagenlecleucel have been used to mostly treat patients with diffuse large b-cell lymphoma in the outpatient setting who are receiving the CAR T-cell therapies prior to failure on 2 prior lines of therapy.

Hillmen Highlights Acalabrutinib’s Tolerability Vs Ibrutinib in Previously Treated CLL

June 12th 2021

The next-generation, selective BTK inhibitor acalabrutinib demonstrated noninferiority to ibrutinib in terms of progression-free survival in patients with previously treated chronic lymphocytic leukemia in the phase 3 ELEVATE-RR trial.

Zanubrutinib Demonstrates Impressive Responses in Relapsed/Refractory CLL

June 11th 2021

Zanubrutinib continued to induce deep responses with acceptable tolerability in patients with relapsed/refractory chronic lymphocytic leukemia, including those with high-risk cytogenetics.

Axi-Cel Provides Durable Responses in Higher-Risk Follicular Lymphoma and MZL, Regardless of POD24 Status

June 11th 2021

Axicabtagene ciloleucel demonstrated significant clinical activity with durable responses in patients with relapsed/refractory indolent non-Hodgkin lymphoma who experienced disease progression within 24 months from initiation of the first anti-CD20–containing chemotherapy, which is a high-risk clinical feature.

Lenalidomide/Rituximab Continues to Improve PFS in iNHL, MCL

June 11th 2021

The combination of lenalidomide and rituximab continued to improve progression-free survival with durable outcomes and a manageable safety profile in patients with indolent B-cell non-Hodgkin lymphomas and mantle cell lymphomas.

Dr. Hillmen on Results With Acalabrutinib in CLL

June 11th 2021

Peter Hillmen, MD, PhD, discusses results reported with acalabrutinib in patients with chronic lymphocytic leukemia, as demonstrated in a phase 3 trial.

Dr. Wang on the Potential Impact of Menin Inhibitors in AML

June 11th 2021

Eunice Wang, MD, discusses the potential impact of menin inhibitors on the treatment of acute myeloid leukemia.